Greiling, Teri
Young, Melodie
Seal, Melissa S.
Higham, Robert C.
Armstrong, April
Funding for this research was provided by:
Arcutis Biotherapeutics
Article History
Received: 13 April 2024
Accepted: 20 May 2024
First Online: 14 June 2024
Declarations
:
: Teri Greiling has received investigator fees, speaker fees, clinical research grants, and/or honoraria from Arcutis Biotherapeutics, Inc. Melodie Young has received investigator fees, speaker fees, clinical research grants, and/or honoraria from AbbVie, Arcutis Biotherapeutics, Inc., Celgene Corporation, Eli Lilly, Janssen, Merck/Sun, Novartis, and UCB. April Armstrong has served as a research investigator, scientific adviser, or speaker to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. Melissa S. Seal and Robert C. Higham are employees of Arcutis Biotherapeutics, Inc.
: The trial was conducted in accordance with the principles of the Declaration of Helsinki of 1964 and its later amendments and Good Clinical Practice guidelines of the International Council for Harmonisation. Before enrollment of patients, the study protocol and informed consent form were reviewed and approved by an appropriate institutional review board or independent ethics committee. Participants provided consent to participate in the survey and to report data in aggregate, not individual participant data.